Waheeta Hopper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Waheeta Hopper has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Kesavan Dineshkumar
4 shared publicationsAngeline Julius
Department of Biotechnology, School of Bioengineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Chennai 603 203, India
3 shared publicationsThangaraju Tamilvanan
3 shared publicationsA. Mahadevan
University of Madras
2 shared publications- Abdul R Ahameethunisa
Department of Bioinformatics, School of Bioengineering, Faculty of Engineering & Technology, SRM University, Kattankulathur, Tamil Nadu 603203, India
2 shared publications Baby Joseph
Department of Research, Hindustan Institute of Technology and Science, Chennai, Tamil Nadu, India
2 shared publications
Latest Publications
- Open Access
- 21 March 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Inhibition of Aldose Reductase by Novel Phytocompounds: A Heuristic Approach to Treating Diabetic Retinopathy
Aldose reductase (ALR2) activation in the polyol pathway has been implicated as the primary mechanism for the progression of diabetic retinopathy. Most of the aldose reductase inhibitors (ARIs), used for the treatment of diabetic complications, were withdrawn due to ineffective treatment and adverse side effects caused by nonspecificity. Epalrestat, a carboxylic acid inhibitor, is the only ARI used for the treatment of diabetic neuropathy, though associated with minor side effects to 8% of the treated population. Our study exploited the interactions of Epalrestat-ALR2 crystal structure for the identification of specific phytocompounds that could inhibit human lens ALR2. 3D structures of plant compounds possessing antidiabetic property were retrieved from PubChem database for inhibition analysis, against human lens ALR2. Among the shortlisted compounds, Agnuside and Eupalitin-3-O-galactoside inhibited lens ALR2 with IC50 values of 22.4 nM and 27.3 nM, respectively, compared to the drug Epalrestat (98 nM), indicating high potency of these compounds as ALR2 inhibitors. IC50 concentration of the identified ARIs was validated in vitro using ARPE-19 cells. The in silico and in vitro approaches employed to identify and validate specific and potent ALR2 inhibitors resulted in the identification of phytocompounds with potency equal to or better than the ALR2 inhibiting drug, Epalrestat.
- 21 March 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-10
Open AccessInhibition of Aldose Reductase by Novel Phytocompounds: A Heuristic Approach to Treating Diabetic Retinopathy
Aldose reductase (ALR2) activation in the polyol pathway has been implicated as the primary mechanism for the progression of diabetic retinopathy. Most of the aldose reductase inhibitors (ARIs), used for the treatment of diabetic complications, were withdrawn due to ineffective treatment and adverse side effects caused by nonspecificity. Epalrestat, a carboxylic acid inhibitor, is the only ARI used for the treatment of diabetic neuropathy, though associated with minor side effects to 8% of the treated population. Our study exploited the interactions of Epalrestat-ALR2 crystal structure for the identification of specific phytocompounds that could inhibit human lens ALR2. 3D structures of plant compounds possessing antidiabetic property were retrieved from PubChem database for inhibition analysis, against human lens ALR2. Among the shortlisted compounds, Agnuside and Eupalitin-3-O-galactoside inhibited lens ALR2 with IC50 values of 22.4 nM and 27.3 nM, respectively, compared to the drug Epalrestat (98 nM), indicating high potency of these compounds as ALR2 inhibitors. IC50 concentration of the identified ARIs was validated in vitro using ARPE-19 cells. The in silico and in vitro approaches employed to identify and validate specific and potent ALR2 inhibitors resulted in the identification of phytocompounds with potency equal to or better than the ALR2 inhibiting drug, Epalrestat.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4230788
In Silico and In Vitro Screening of Natural Compounds as Broad‐Spectrum β‐Lactamase Inhibitors against Acinetobacter baumannii New Delhi Metallo‐β‐lactamase‐1 (NDM‐1)
Antibiotic resistance is one of the significant problems globally; there is an increase in resistance with introducing every new class of antibiotics. Further, this has become one of the reasons for arising of new resistance mechanisms in Acinetobacter baumannii. In this study, we have screened natural compounds as a possible inhibitor against the NDM‐1 β‐lactamase enzyme from A. baumannii using a combination of in silico methods and in vitro evaluation. The database of natural compounds was screened against NDM‐1 protein, using Glide docking, followed by QM‐polarised ligand docking (QPLD). When the screened hits were validated in vitro, withaferin A and mangiferin had good IC50 values in reducing the activity of NDM‐1 enzymes, and their fractional inhibitory concentration index (FICI) was ascertained in combination with imipenem. The withaferin A and mangiferin‐NDM‐1 docking complexes were analyzed for structural stability by molecular dynamic simulation analysis using GROMACS for 100 ns. The molecular properties of the natural compounds were then calculated using density functional theory (DFT). Withaferin A and mangiferin showed promising inhibitory activity and can be a natural compound candidate inhibitor synergistically used along with carbapenems against NDM‐1 producing A. baumannii.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4230788
Open AccessIn Silico and In Vitro Screening of Natural Compounds as Broad‐Spectrum β‐Lactamase Inhibitors against Acinetobacter baumannii New Delhi Metallo‐β‐lactamase‐1 (NDM‐1)
Antibiotic resistance is one of the significant problems globally; there is an increase in resistance with introducing every new class of antibiotics. Further, this has become one of the reasons for arising of new resistance mechanisms in Acinetobacter baumannii. In this study, we have screened natural compounds as a possible inhibitor against the NDM‐1 β‐lactamase enzyme from A. baumannii using a combination of in silico methods and in vitro evaluation. The database of natural compounds was screened against NDM‐1 protein, using Glide docking, followed by QM‐polarised ligand docking (QPLD). When the screened hits were validated in vitro, withaferin A and mangiferin had good IC50 values in reducing the activity of NDM‐1 enzymes, and their fractional inhibitory concentration index (FICI) was ascertained in combination with imipenem. The withaferin A and mangiferin‐NDM‐1 docking complexes were analyzed for structural stability by molecular dynamic simulation analysis using GROMACS for 100 ns. The molecular properties of the natural compounds were then calculated using density functional theory (DFT). Withaferin A and mangiferin showed promising inhibitory activity and can be a natural compound candidate inhibitor synergistically used along with carbapenems against NDM‐1 producing A. baumannii.
- Open Access
- 7 January 2019
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 12 (1) , 168-172
COMPUTATIONAL ANALYSIS OF COMPOUNDS FROM OCIMUM SANCTUM FOR ANTICANCER ACTIVITY AGAINST ORAL SQUAMOUS CELL CARCINOMA
Objective: The objectives of this research are to identify the potentials of active phytochemicals from Ocimum sanctum as anticancer agents, by inhibiting the epidermal growth factor receptor (EGFR), one of the highly expressed proteins inducing metastasis in oral squamous cell carcinoma (OSCC) as well as other cancers.Methods: The phytochemicals found in O. sanctum were identified and downloaded from online chemical databases. The target protein was retrieved from the Protein Data Bank. Virtual screening using glide protocols of high throughput virtual screening and molecular docking using standard precision and extra precision (XP) were carried out. The binding energies and the important physicochemical properties of the compounds were also determined.Results: A total number of 210 compounds from O. sanctum were screened against EGFR. Lipinski rule was followed to find the compounds with favorable drug absorptive properties. The shortlisted compounds, namely luteolin, apigenin, and isothymusin, possess high Glide scores (kcal/mol) of −9.98, −9.51, and −9.45 and binding energies (kcal/mol) of −42.63, −48.28, and −44.95, respectively.Conclusion: Among the three compounds, Isothymusin was not yet been reported to posess anticancer activity. Our study suggest this compound as a potential chemotherapeutic agent for treating OSCC. They function by inhibiting the activity of metastasis - inducing protein EGFR.
- 7 January 2019
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 12 (1) , 168-172
Open AccessCOMPUTATIONAL ANALYSIS OF COMPOUNDS FROM OCIMUM SANCTUM FOR ANTICANCER ACTIVITY AGAINST ORAL SQUAMOUS CELL CARCINOMA
Objective: The objectives of this research are to identify the potentials of active phytochemicals from Ocimum sanctum as anticancer agents, by inhibiting the epidermal growth factor receptor (EGFR), one of the highly expressed proteins inducing metastasis in oral squamous cell carcinoma (OSCC) as well as other cancers.Methods: The phytochemicals found in O. sanctum were identified and downloaded from online chemical databases. The target protein was retrieved from the Protein Data Bank. Virtual screening using glide protocols of high throughput virtual screening and molecular docking using standard precision and extra precision (XP) were carried out. The binding energies and the important physicochemical properties of the compounds were also determined.Results: A total number of 210 compounds from O. sanctum were screened against EGFR. Lipinski rule was followed to find the compounds with favorable drug absorptive properties. The shortlisted compounds, namely luteolin, apigenin, and isothymusin, possess high Glide scores (kcal/mol) of −9.98, −9.51, and −9.45 and binding energies (kcal/mol) of −42.63, −48.28, and −44.95, respectively.Conclusion: Among the three compounds, Isothymusin was not yet been reported to posess anticancer activity. Our study suggest this compound as a potential chemotherapeutic agent for treating OSCC. They function by inhibiting the activity of metastasis - inducing protein EGFR.
- Open Access
- 7 January 2019
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 12 (1) , 168-172
COMPUTATIONAL ANALYSIS OF COMPOUNDS FROM OCIMUM SANCTUM FOR ANTICANCER ACTIVITY AGAINST ORAL SQUAMOUS CELL CARCINOMA
Objective: The objectives of this research are to identify the potentials of active phytochemicals from Ocimum sanctum as anticancer agents, by inhibiting the epidermal growth factor receptor (EGFR), one of the highly expressed proteins inducing metastasis in oral squamous cell carcinoma (OSCC) as well as other cancers.Methods: The phytochemicals found in O. sanctum were identified and downloaded from online chemical databases. The target protein was retrieved from the Protein Data Bank. Virtual screening using glide protocols of high throughput virtual screening and molecular docking using standard precision and extra precision (XP) were carried out. The binding energies and the important physicochemical properties of the compounds were also determined.Results: A total number of 210 compounds from O. sanctum were screened against EGFR. Lipinski rule was followed to find the compounds with favorable drug absorptive properties. The shortlisted compounds, namely luteolin, apigenin, and isothymusin, possess high Glide scores (kcal/mol) of −9.98, −9.51, and −9.45 and binding energies (kcal/mol) of −42.63, −48.28, and −44.95, respectively.Conclusion: Among the three compounds, Isothymusin was not yet been reported to posess anticancer activity. Our study suggest this compound as a potential chemotherapeutic agent for treating OSCC. They function by inhibiting the activity of metastasis - inducing protein EGFR.
- 7 January 2019
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 12 (1) , 168-172
Open AccessCOMPUTATIONAL ANALYSIS OF COMPOUNDS FROM OCIMUM SANCTUM FOR ANTICANCER ACTIVITY AGAINST ORAL SQUAMOUS CELL CARCINOMA
Objective: The objectives of this research are to identify the potentials of active phytochemicals from Ocimum sanctum as anticancer agents, by inhibiting the epidermal growth factor receptor (EGFR), one of the highly expressed proteins inducing metastasis in oral squamous cell carcinoma (OSCC) as well as other cancers.Methods: The phytochemicals found in O. sanctum were identified and downloaded from online chemical databases. The target protein was retrieved from the Protein Data Bank. Virtual screening using glide protocols of high throughput virtual screening and molecular docking using standard precision and extra precision (XP) were carried out. The binding energies and the important physicochemical properties of the compounds were also determined.Results: A total number of 210 compounds from O. sanctum were screened against EGFR. Lipinski rule was followed to find the compounds with favorable drug absorptive properties. The shortlisted compounds, namely luteolin, apigenin, and isothymusin, possess high Glide scores (kcal/mol) of −9.98, −9.51, and −9.45 and binding energies (kcal/mol) of −42.63, −48.28, and −44.95, respectively.Conclusion: Among the three compounds, Isothymusin was not yet been reported to posess anticancer activity. Our study suggest this compound as a potential chemotherapeutic agent for treating OSCC. They function by inhibiting the activity of metastasis - inducing protein EGFR.
- Open Access
- 1 January 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 109, 708-715
A non-invasive, multi-target approach to treat diabetic retinopathy
- 1 January 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 109, 708-715
Open AccessA non-invasive, multi-target approach to treat diabetic retinopathy
- Open Access
In silico modeling and simulation of neuroendocrine-immune modulation through adrenergic and 17β-estradiol receptors in lymphocytes show differential activation of cyclic adenosine monophosphate (cAMP)
Sympathetic innervation of lymphoid organs and presence of 17β-estradiol (estrogen or E 2 ) and adrenergic receptors (ARs) on lymphocytes suggests that sympathetic stimulation and hormonal activation may influence immune functions. Simulation of these pathways may help to understand the dynamics of neuroendocrine-immune modulation at the cellular and molecular level. Dose- and receptor-dependent effects of 17β-estradiol and AR sub-type-specific agonists were established in vitro on lymphocytes from young male Sprague-Dawley rats and modeled in silico using MATLAB Simbiology toolbox. Kinetic principles were assigned to define receptor-ligand dynamics and concentration/time plots were obtained using Ode15s solvers at different time intervals for key regulatory molecules. Comparisons were drawn between in silico and in vitro data for validating the constructed model with sensitivity analysis of key regulatory molecules to assess their individual impacts on the dynamics of the system. Adrenergic activation triggered pro-apoptotic signals while 17β-estradiol enhanced survival signals showing contradictory effects as observed in vitro. Treatment of lymphocytes with 17β-estradiol shows ten-fold increase in survival signals in a dose-dependent manner. cAMP (cyclic adenosine monophosphate) activation is crucial for the activation of survival signals through p-ERK (Extracellular Signal-Regulated Kinase) and p-CREB (cAMP Responsive Element Binding) protein. Thus, the cross-talk between 17β-estradiol and adrenergic signaling pathways determines lymphocyte functions in a receptor subtype- and co-activation-dependent manner in health and disease.
Open AccessIn silico modeling and simulation of neuroendocrine-immune modulation through adrenergic and 17β-estradiol receptors in lymphocytes show differential activation of cyclic adenosine monophosphate (cAMP)
Sympathetic innervation of lymphoid organs and presence of 17β-estradiol (estrogen or E 2 ) and adrenergic receptors (ARs) on lymphocytes suggests that sympathetic stimulation and hormonal activation may influence immune functions. Simulation of these pathways may help to understand the dynamics of neuroendocrine-immune modulation at the cellular and molecular level. Dose- and receptor-dependent effects of 17β-estradiol and AR sub-type-specific agonists were established in vitro on lymphocytes from young male Sprague-Dawley rats and modeled in silico using MATLAB Simbiology toolbox. Kinetic principles were assigned to define receptor-ligand dynamics and concentration/time plots were obtained using Ode15s solvers at different time intervals for key regulatory molecules. Comparisons were drawn between in silico and in vitro data for validating the constructed model with sensitivity analysis of key regulatory molecules to assess their individual impacts on the dynamics of the system. Adrenergic activation triggered pro-apoptotic signals while 17β-estradiol enhanced survival signals showing contradictory effects as observed in vitro. Treatment of lymphocytes with 17β-estradiol shows ten-fold increase in survival signals in a dose-dependent manner. cAMP (cyclic adenosine monophosphate) activation is crucial for the activation of survival signals through p-ERK (Extracellular Signal-Regulated Kinase) and p-CREB (cAMP Responsive Element Binding) protein. Thus, the cross-talk between 17β-estradiol and adrenergic signaling pathways determines lymphocyte functions in a receptor subtype- and co-activation-dependent manner in health and disease.
- Open Access
- 1 April 2018
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- Vol. 10 (4) , 98-100
ANALYSIS OF MOLECULAR DOCKING EFFICIENCY OF CLEISTANTHIN-A, AS AN ALTERNATIVE FOR NICOTINE ADDICTION
Objective: The present research was aimed to understand the molecular docking efficiency of a plant-derived compound cleistanthin-A and a common ingredient in tobacco consumption nicotine with nicotinic acetylcholine receptor (nAChR).Methods: The 3-D structure of nAChR was retrieved from the protein data bank (ID 5AFH). Ligand was obtained from the PUBCHEM. The in silico protocol comprised of three steps: high-throughput virtual screening (HTVS), standard precision (SP) and extra precision (XP). The screened molecules were ranked accordingly using glide score. Schrödinger tool was used to perform the docking analysis.Results: The binding efficiency of the nicotine and cleistanthin-A was found to be docked at the cys-cys loop of the receptor. Based upon the glide score and glide energy it can be reported that, nicotine binding can be inhibited by the binding of cleistanthin-A to the nAChR.Conclusion: The docking efficiency of cleistanthin-A was good compared to nicotine towards nAChR. Hence, cleistanthin–A was derived as a better choice as an alternative for nicotine in smoke therapy.
- 1 April 2018
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- Vol. 10 (4) , 98-100
Open AccessANALYSIS OF MOLECULAR DOCKING EFFICIENCY OF CLEISTANTHIN-A, AS AN ALTERNATIVE FOR NICOTINE ADDICTION
Objective: The present research was aimed to understand the molecular docking efficiency of a plant-derived compound cleistanthin-A and a common ingredient in tobacco consumption nicotine with nicotinic acetylcholine receptor (nAChR).Methods: The 3-D structure of nAChR was retrieved from the protein data bank (ID 5AFH). Ligand was obtained from the PUBCHEM. The in silico protocol comprised of three steps: high-throughput virtual screening (HTVS), standard precision (SP) and extra precision (XP). The screened molecules were ranked accordingly using glide score. Schrödinger tool was used to perform the docking analysis.Results: The binding efficiency of the nicotine and cleistanthin-A was found to be docked at the cys-cys loop of the receptor. Based upon the glide score and glide energy it can be reported that, nicotine binding can be inhibited by the binding of cleistanthin-A to the nAChR.Conclusion: The docking efficiency of cleistanthin-A was good compared to nicotine towards nAChR. Hence, cleistanthin–A was derived as a better choice as an alternative for nicotine in smoke therapy.
- Open Access
- 15 February 2018
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 10 (1) , 62-65
Natural Aldose Reductase Inhibitors Act as Potent Agonists of PPARγ
Background: Diabetes and cancer have been the leading cause of mortality all over the world. Studies on association between diabetes and cancers over a decade indicate a positive relationship between them. Epidemiologic evidence suggests that people with diabetes are prone to various types of cancers. This work suggests a novel strategy for the treatment of diabetes and cancers. Methods: Extra-precision (XP) docking strategy, was used to predict the binding interactions of partial, full agonists of PPARγ and aldose reductase inhibitors on the PPARγ crystal structures. Binding interactions of PPARγ with the partial agonists, NTzDpa and MEKT76 and the full agonist Rosiglytasone were exploited to identify partial and full agonists of PPARγ among aldose reductase inhibitors. Results: Full and partial agonists of PPARγ inhibit various cancers, by suppressing the factors associated with neovascularisation. Partial agonists of PPARγ are prefered than full agonists like thiazolidinediones, reported to have serious side effects. Aldose reductase inhibitors used to treat diabetic complications, show binding interactions similar to the agonists of PPARγ and could hold a heuristic approach in treating diabetes and cancers. Conclusion: Aldose reductase inhibitors, tetrahydrocurcumin, catechin-5-O-gallate, rutin, (2S)-2’- methoxykurarinone, epalrestat, 8-lavandulylkaempferol depict interactions of partial agonists of PPARγ and could be further studied for their dual role as agonist and antagonist of the proteins PPARγ and Aldose reductase respectively. Key words: Aldose reductase inhibitors, Cancer treatment, Diabetes, Natural compounds, PPARγ agonists.
- 15 February 2018
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 10 (1) , 62-65
Open AccessNatural Aldose Reductase Inhibitors Act as Potent Agonists of PPARγ
Background: Diabetes and cancer have been the leading cause of mortality all over the world. Studies on association between diabetes and cancers over a decade indicate a positive relationship between them. Epidemiologic evidence suggests that people with diabetes are prone to various types of cancers. This work suggests a novel strategy for the treatment of diabetes and cancers. Methods: Extra-precision (XP) docking strategy, was used to predict the binding interactions of partial, full agonists of PPARγ and aldose reductase inhibitors on the PPARγ crystal structures. Binding interactions of PPARγ with the partial agonists, NTzDpa and MEKT76 and the full agonist Rosiglytasone were exploited to identify partial and full agonists of PPARγ among aldose reductase inhibitors. Results: Full and partial agonists of PPARγ inhibit various cancers, by suppressing the factors associated with neovascularisation. Partial agonists of PPARγ are prefered than full agonists like thiazolidinediones, reported to have serious side effects. Aldose reductase inhibitors used to treat diabetic complications, show binding interactions similar to the agonists of PPARγ and could hold a heuristic approach in treating diabetes and cancers. Conclusion: Aldose reductase inhibitors, tetrahydrocurcumin, catechin-5-O-gallate, rutin, (2S)-2’- methoxykurarinone, epalrestat, 8-lavandulylkaempferol depict interactions of partial agonists of PPARγ and could be further studied for their dual role as agonist and antagonist of the proteins PPARγ and Aldose reductase respectively. Key words: Aldose reductase inhibitors, Cancer treatment, Diabetes, Natural compounds, PPARγ agonists.
- Open Access
- 1 February 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (2) , 181-188
ENERGY-BASED PHARMACOPHORE MODELING, VIRTUAL SCREENING, AND MOLECULAR DYNAMICS TO IDENTIFY POTENTIAL INHIBITORS FOR GLYCOGEN SYNTHASE KINASE 3 BETA
Objective: Glycogen synthase kinase 3 beta (GSK3β) is one of the main targets for wound healing activity. Our objective is to identify novel inhibitors for GSK3β using in silico approach.Methods: Grid-based molecular docking, energy-based pharmacophore (e-pharmacophore) modeling, and molecular dynamics (MD) studies were performed for phytocompounds with GSK3β and compared with standard drugs using Schrodinger software.Results: The glide scores and the molecular interactions of the phytocompounds were well comparable to the standard drugs. The MD was performed for the target bound to the best scoring ligand, entagenic acid. The pharmacophore features of this docked complex were modeled as e-pharmacophore. The constructed e-pharmacophore model was screened against phytocompounds retrieved from literature to identify the ligands with similar pharmacophore features.Conclusion: The glide scores of fukinolic acid, cimicifugic acid, and linarin were −10.99, −8.28, and −7.25 kcal/mol, respectively. The further 50 nanoseconds MD study determined the stability of GSK3β-linarin complex. Nitrofurazone and sulfathiazole drugs can lead to systemic side effects. Hence, it is concluded that linarin could be a potent wound healing compound against GSK3β.
- 1 February 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (2) , 181-188
Open AccessENERGY-BASED PHARMACOPHORE MODELING, VIRTUAL SCREENING, AND MOLECULAR DYNAMICS TO IDENTIFY POTENTIAL INHIBITORS FOR GLYCOGEN SYNTHASE KINASE 3 BETA
Objective: Glycogen synthase kinase 3 beta (GSK3β) is one of the main targets for wound healing activity. Our objective is to identify novel inhibitors for GSK3β using in silico approach.Methods: Grid-based molecular docking, energy-based pharmacophore (e-pharmacophore) modeling, and molecular dynamics (MD) studies were performed for phytocompounds with GSK3β and compared with standard drugs using Schrodinger software.Results: The glide scores and the molecular interactions of the phytocompounds were well comparable to the standard drugs. The MD was performed for the target bound to the best scoring ligand, entagenic acid. The pharmacophore features of this docked complex were modeled as e-pharmacophore. The constructed e-pharmacophore model was screened against phytocompounds retrieved from literature to identify the ligands with similar pharmacophore features.Conclusion: The glide scores of fukinolic acid, cimicifugic acid, and linarin were −10.99, −8.28, and −7.25 kcal/mol, respectively. The further 50 nanoseconds MD study determined the stability of GSK3β-linarin complex. Nitrofurazone and sulfathiazole drugs can lead to systemic side effects. Hence, it is concluded that linarin could be a potent wound healing compound against GSK3β.
- 1 November 2017
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 10 (11) , 173
INHIBITION OF ADVANCED GLYCATION END-PRODUCT FORMATION BY QUERCETIN AND CATECHIN: AN ALTERNATIVE THERAPY FOR TREATING DIABETIC COMPLICATIONS
Objective: The objective of this research was to determine early advanced glycation end-product (AGE) inhibition by natural aldose reductase inhibitors (ARIs), quercetin and catechin.Methods: The assay mixture (4 ml) consisted of 2 ml of 50 mM phosphate-buffered saline (pH 7.4), 50 μg/μl bovine serum albumin (BSA), and 2 mM glucose with or without the inhibitor. The test samples were treated with three different concentrations (10 mM, 20 mM, and 40 mM) of quercetin and catechin. High-throughput screening-based assay was adapted to perform the BSA-glucose test to determine the induction of AGE formation and its inhibition by quercetin, and catechin, using the fluorescence of the AGE-BSA sample at excitation and emission wavelengths of 350 and 450 nm.Result: The ARIs, quercetin and catechin inhibited early glycation with an inhibitory concentration value of 15.58 mM and 35.01 mM, respectively.Conclusion: The suppression of AGEs formation by natural inhibitors of aldose reductase would provide an alternative approach to the control of diabetic complications.
- 1 November 2017
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 10 (11) , 173
INHIBITION OF ADVANCED GLYCATION END-PRODUCT FORMATION BY QUERCETIN AND CATECHIN: AN ALTERNATIVE THERAPY FOR TREATING DIABETIC COMPLICATIONS
Objective: The objective of this research was to determine early advanced glycation end-product (AGE) inhibition by natural aldose reductase inhibitors (ARIs), quercetin and catechin.Methods: The assay mixture (4 ml) consisted of 2 ml of 50 mM phosphate-buffered saline (pH 7.4), 50 μg/μl bovine serum albumin (BSA), and 2 mM glucose with or without the inhibitor. The test samples were treated with three different concentrations (10 mM, 20 mM, and 40 mM) of quercetin and catechin. High-throughput screening-based assay was adapted to perform the BSA-glucose test to determine the induction of AGE formation and its inhibition by quercetin, and catechin, using the fluorescence of the AGE-BSA sample at excitation and emission wavelengths of 350 and 450 nm.Result: The ARIs, quercetin and catechin inhibited early glycation with an inhibitory concentration value of 15.58 mM and 35.01 mM, respectively.Conclusion: The suppression of AGEs formation by natural inhibitors of aldose reductase would provide an alternative approach to the control of diabetic complications.